Prevalence of lower urinary tract symptoms in patients with cardiovascular disease

Material and methods Patients hospitalized in a tertiary cardiology department due to a primary diagnosis of cardiovascular disease (including coronary artery disease, heart failure and arrhythmia) were included in the study. The first stage of the study included taking the clinical history, physica...

Full description

Saved in:
Bibliographic Details
Published in:Central European journal of urology 2021-01, Vol.74 (2), p.190-195
Main Authors: Semczuk-Kaczmarek, Karolina, Rys-Czaporowska, Anna, Platek, Anna E, Szymański, Filip M
Format: Article
Language:English
Subjects:
Atherosclerosis
Cardiac arrhythmia
Cardiology
Cardiovascular disease
Chronic illnesses
Coronary vessels
Diabetes
Erectile dysfunction
Heart failure
Hypertension
Metabolism
Original Paper
Population
Prostate
Questionnaires
Regression analysis
Risk factors
Urinary incontinence
Urogenital system
Variance analysis
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Material and methods Patients hospitalized in a tertiary cardiology department due to a primary diagnosis of cardiovascular disease (including coronary artery disease, heart failure and arrhythmia) were included in the study. The first stage of the study included taking the clinical history, physical examination, body measurements, blood test, and imaging studies were made, in order to confirm the diagnosis of cardiovascular diseases and describe the risk factors. Several factors might be responsible for the relationship between CVD and LUTS: metabolic syndrome, chronic inflammation, atherosclerosis-induced pelvic ischemia, increased Rho-kinase activation, impaired nitric-oxide synthase pathway in the endothelium, autonomic hyperactivity with sympathetic dysregulation, declining testosterone levels [13, 14]. The recent studies indicate that healthy lifestyles, antihypertensive therapy with angiotensin II receptor blockers and lipid-lowering therapy (statins) reduce not only cardiovascular mortality but also might reduce prevalence and severity of lower urinary tract symptoms [13].
ISSN:2080-4873
2080-4806
2080-4873
DOI:10.5173/ceju.2021.0370.R1